LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

Accueil・Liste d'Actions・Merck & Co Inc.

Merck & Co Inc.

Ouvert

SecteurSoins de santé

112.3 0.95

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

111.24

Max

113.61

Chiffres clés
By Trading Economics
Revenu	-7.2B -4.2B
Ventes	-114M 16B
P/E Moyenne du Secteur	31.507 49.8
BPA	-1.28
Rendement du dividende	2.92
Marge bénéficiaire	-26.053
Employés	73,000
EBITDA	-6.2B -1.9B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+22.44% upside

Dividendes
By Dow Jones
Rendement du dividende Moyenne du Secteur	2.92% 2.25%
Prochains Résultats	4 août 2026
Date du Prochain Dividende	7 juil. 2026
Date du Prochain Détachement de Dividende	15 juin 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	7.1B 279B
Ouverture précédente	111.35
Clôture précédente	112.3

Sentiment de l'Actualité

By Acuity

49%

51%

150 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

76.03 / 83.28 Support & Résistance

Merck & Co Inc. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2026, 14:20 UTC

Résultats

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 avr. 2026, 10:45 UTC

Résultats

Merck 1Q Sales Rise on Continued Keytruda Growth

5 mai 2026, 18:12 UTC

Résultats

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mai 2026, 13:54 UTC

Résultats

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 mai 2026, 12:48 UTC

Acquisitions, Fusions, Rachats

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 mai 2026, 12:48 UTC

Acquisitions, Fusions, Rachats

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 mai 2026, 12:47 UTC

Acquisitions, Fusions, Rachats

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 mai 2026, 12:45 UTC

Acquisitions, Fusions, Rachats

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 mai 2026, 18:35 UTC

Résultats

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 mai 2026, 14:53 UTC

Résultats

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 avr. 2026, 13:27 UTC

Résultats

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 avr. 2026, 10:47 UTC

Résultats

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 avr. 2026, 10:30 UTC

Résultats

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck 1Q Animal Health Sales Up 13% >MRK

30 avr. 2026, 10:30 UTC

Résultats

Merck 1Q Sales $16.29B >MRK

Comparaison

Variation de prix

Merck & Co Inc. prévision

Objectif de Prix

By TipRanks

22.44% hausse

Prévisions sur 12 Mois

Moyen 136.37 USD 22.44%

Haut 179 USD

Bas 112 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

21 ratings

Achat

Maintien

Vente

Basé sur 21 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

76.03 / 83.28Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

150 / 347Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.